RFL Stock Summary and Trading Ideas (Rafael Holdings Class B | NYSE:RFL)

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Rafael Holdings Class B trades on the NYSE stock market under the symbol RFL.

As of December 29, 2025, RFL stock price declined to $1.19 with 206,513 million shares trading.

RFL has a beta of 0.72, meaning it tends to be less sensitive to market movements. RFL has a correlation of 0.04 to the broad based SPY ETF.

RFL has a market cap of $61.61 million. This is considered a Micro Cap stock.

In the last 3 years, RFL traded as high as $3.19 and as low as $1.15.

The top ETF exchange traded funds that RFL belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFAC.

RFL has underperformed the market in the last year with a price return of -26.5% while the SPY ETF gained +15.6%. RFL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.5% and -18.5%, respectively, while the SPY returned +4.2% and +1.2%, respectively.

RFL support price is $1.13 and resistance is $1.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RFL shares will trade within this expected range on the day.